Earlier this week, Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) announced that it has received a patent in China for its synthetic anti-infective drug candidates, RECCE 327 and RECCE 529. CEO James Graham joined us to discuss how the patent enhances its global intellectual property position, covering methods of use, administration, and manufacture. The protection extends through 2041.
Highlights
- Recce Pharmaceuticals has received a Chinese patent for its anti-infective candidates RECCE 327 and 529.
- The patent covers methods of use, administration, and manufacture for bacterial and viral infections.
- It extends Recce’s potential market exclusivity in China to 2041.
- RECCE 327 is focused on bacterial infections; RECCE 529 targets viral infections.
- The Chinese pharmaceutical market is valued at 5.00 billion USD with a 6% CAGR.
- Patent supports treatment claims for conditions like ABSSSI, diabetic foot ulcers, UTIs, gonorrhoea, and pneumonia.
- Recce is conducting a Phase III trial in Indonesia with potential approval across ASEAN nations.
- Interim trial data is expected in Q1 2026.
- A Phase III trial targeting ABSSSI is planned in the US following successful Phase II results in Australia.
Growing market in China
The company told investors that RECCE 327 targets bacterial infections, while RECCE 529 is positioned for its antiviral activity. The new patent enables the company to pursue a broader market presence in Asia, particularly in China’s US$5 billion pharmaceutical sector, which is growing at a rate of 6% per year.
The patent covers a wide range of infections including ABSSSI, diabetic foot ulcers, urinary tract infections, gonorrhoea, and pneumonia. The company is currently conducting a Phase III trial in Indonesia focused on diabetic foot ulcer infections, with interim data expected in the first quarter of 2026. Recce highlighted that approval in Indonesia could facilitate access to other ASEAN countries via shared regulatory pathways.
US launch
In the US, the company plans to launch a Phase III trial targeting ABSSSI, following a successful Phase II study in Australia.
Recce said the intellectual property milestone supports its commercial and regulatory strategy across multiple high-growth international markets.